Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1992-05-14
1994-05-17
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514142, 514215, 514217, 514297, 514346, 514411, 514923, A61K 3166, A61K 3155, A61K 3144, A61K 3140
Patent
active
053128176
ABSTRACT:
The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of fatigue syndromes, including chronic fatigue syndrome, post-infectious fatigue syndromes, fatigue syndromes associated with human immunodeficiency virus (HIV) infection or with preeclampsia. The acetyl cholinesterase is preferably one that acts substantially selectively at nicotinic receptor sites, and which has selectivity for acetyl cholinesterase as opposed to butyryl cholinesterase. Compounds of the invention include galanthamine and galanthamine derivatives.
REFERENCES:
Chemical Abstracts, vol. 47, No. 6959 (1952).
"A Report-Chronic Fatigue Syndrome: Guidelines for Research," Journal of the Royal Society of Medicine, vol. 84, Feb. 1991; pp. 118-121.
Paskov, "Galanthamine", Handbook Exp. Pharmac., 79, pp. 653-672, 1986.
Bretagne and Valetta, "Essais Clinques en Anesthesiologie D'un Nouvel Anticholinesterasique La Galanthamine" (in French), Anesth. Analges, 22, pp. 285-292, 1965.
L. Wislicki, "Nivalin (Galanthamine Hydrobromide), An Additional Decurarizing Agent, Some Introductory Observations," Brit. J. Anaesth., 39, pp. 963-968, 1967.
D. A. Cozanitis and E. Toivaeea, "A Comparative Study of Galanthamine Hydrobromide and Atropine/Neostigmine in Conscious Volunteers," Der Anaesthesist, pp. 416-421, 1971.
T. Thomsen and H. Kewitz, "Selective Inhibition of Human Acetylcholinesterase by Galanthamine In Vitro and In Vivo," Life Sciences, vol. 46, pp. 1553-1558, 1990.
T. Thomsen, U. Bickel, J. P. Fischer, H. Kewitz; "Galanthamine Hydrobromide in a Long-Term Treatment of Alzheimer's Disease," Dimentia, 1:46-51, pp. 46-51, 1990.
T. Thomsen, H. Kewitz, O. Pleul; "Estimation of Cholinesterase Activity (EC 3.1.1.7; 3.1.1.8) in Undiluted Plasma and Erythrocytes as a Tool for Measuring In Vivo Effects of Reversible Inhibitors," J. Clin. Chem. Clin. Biochem., 26, pp. 469-475, 1988.
S. Straus, "History of Chronic Fatigue Syndrome," Reviews of Infectious Diseases, vol. 13, Supplement 1, pp. S2-S7, Jan.-Feb. 1991.
D. Buchwald and A. Komaroff, "Review of Laboratory Findings for Patients with Chronic Fatigue Syndrome," Reviews of Infections Diseases, vol. 13, Supplement 1, S12-S18, Jan.-Feb. 1991.
N. M. Gantz and G. P. Holmes, "Treatment of Patients with Chronic Fatigue Syndrome," Drugs, vol. 38, No. 6, pp. 855-862, 1989.
M. Jindal, "Effect of Methylated Xanthines on Skeletal Muscle", B.J. Medical College, Jan., 1976. D. A. Bruckenstein, The Nerve Terminal Sinauer Associates, Inc., pp. 172-175.
Chemical Abstracts 81:9686h (1974).
Criares T. J.
Waddell Frederick E.
LandOfFree
Treatment of fatigue syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of fatigue syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of fatigue syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-876882